Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Januvia on Bone Metabolism in Type 2 Diabetes
NCT02444364Phase 1Withdrawn
- Sponsor
- University of Missouri
- Start
- May 2015
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sitagliptin in type 2 diabetes mellitus (T2DM), sponsored by University of Missouri. Primary endpoint: Change in Bone Turnover at 6 months. Planned start May 2015; status: withdrawn.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02444364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02444364.